Tenderwize
Wróć do wyszukiwania

Open House Discount Agreements for Certolizumab pegol, ATC L04AB05

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Eisenberg, Germany·Deadline Feb 28, 2027 · 186 days left·Open·Supplies
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Certolizumab pegol , ATC L04AB05

40/100

Ocena szansy

Needs reviewLow complexity
SuppliesOpen
Skąd ta ocena?

Szansa

40 / 100

Złożoność

20 / 100

Czynniki ryzyka

Non-exclusive contracts mean market share is not guaranteed; multiple competitors may participate, diluting potential v...

Buyer may replace open-house contracts with exclusive agreements at any time, terminating these contracts early.

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Supplies contract
  • 1 lot
  • Duration until Apr 2027
  • Conclusion of non-exclusive discount agreements for Certolizumab pegol (ATC L04AB05) under the open-house model.
  • Contracts have uniform terms and conditions, no individual negotiations.
Pokaż pełne podsumowanie

Non-exclusive discount agreement (open-house model) for the active substance Certolizumab pegol (ATC L04AB05), offered by AOK Rheinland-Pfalz/Saarland. All interested pharmaceutical companies meeting eligibility may join at uniform terms. Contracts run max 24 months (earliest start 01.05.2025, ending 30.04.2027). The buyer may replace with exclusive contracts during the term. First submission deadline: 31.03.2025; subsequent monthly deadlines. Notice is a voluntary transparency publication, not a formal EU procurement.

Ryzyka

Non-exclusive contracts mean market share is not guaranteed; multiple competitors may participate, diluting potential v...

Buyer may replace open-house contracts with exclusive agreements at any time, terminating these contracts early.

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Evidence of marketability via Lauer-Taxe listing or AMIce database extract required.

Eligibility

  • Only pharmaceutical products authorized and marketable in Germany are eligible.

Administrative

  • Submission of signed contract documents and required evidence by the specified deadlines.

Kryteria udzielenia

Lot 1

No award criteria are applied as the open-house model accepts all qualifying participants. Eligibility is the sole condition.

Zamawiający

Lokalizacja

Eisenberg, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE271900642

Działalność

Health

Części (1)

LOT-0001

Open House Discount Agreements for Certolizumab pegol, ATC L04AB05

Non-exclusive discount contracts for the supply of pharmaceutical products containing the active substance Certolizumab pegol (ATC L04AB05) to the AOK Rheinland-Pfalz/Saarland. All qualified pharmaceutical companies can join on standard terms. Duration: up to 24 months from 01.05.2025 to 30.04.2027. Rolling entry possible monthly. Uniform conditions, no negotiations. Subject to early termination if buyer awards exclusive contracts.

SuppliesEU fundedElectronic submission

Lokalizacja

Eisenberg, Germany

Czas trwania

Apr 2025 - Apr 2027

Kategoria

Pharmaceutical products

Kryteria udzielenia

No award criteria are applied as the open-house model accepts all qualifying participants. Eligibility is the sole condition.

Termin

Deadline Feb 28, 2027

Szczegóły zamówienia

Data publikacji
12 Mar 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
164685-2025

Dokumenty (1)

Podobne przetargi